**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77461

**Manuscript Type:** MINIREVIEWS

**Clinical presentation, management, screening and surveillance for colorectal cancer during the COVID-19 pandemic**

Akbulut S *et al*. CRC screening and surveillance during COVID-19

Sami Akbulut, Abdirahman Sakulen Hargura, Ibrahim Umar Garzali, Ali Aloun, Cemil Colak

**Sami Akbulut, Abdirahman Sakulen Hargura, Ibrahim Umar Garzali,** Department of Surgery, Inonu University Faculty of Medicine, Malatya 44280, Turkey

**Sami Akbulut, Cemil Colak,** Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya 44280, Turkey

**Abdirahman Sakulen Hargura,** Department of Surgery, Kenyatta University Teaching, Referral and Research Hospital, Nairobi 00100, Kenya

**Ibrahim Umar Garzali,** Department of Surgery, Aminu Kano Teaching Hospital, Kano 700101, Nigeria

**Ali Aloun,** Department of Surgery, King Hussein Medical Center, Amman 11855, Jordan

**Author contributions:** Akbulut S, Hargura AS, Garzali IU and Aloun A performed the majority of the manuscript writing and prepared the figures; Hargura AS and Garzali IU performed data acquisition and manuscript writing; Hargura AS, Garzali IU and Aloun A provided input for writing the paper; Akbulut S and Colak C designed the outline and coordinated the writing of the paper.

**Corresponding author: Sami Akbulut, PhD, Professor,** Department of Surgery, Inonu University Faculty of Medicine, Elazig Yolu 10.Km, Malatya 44280, Turkey. akbulutsami@gmail.com

**Received:** May 1, 2022

**Revised:** May 29, 2022

**Accepted:** August 6, 2022

**Published online:** September 16, 2022

**Abstract**

Management of colorectal cancer (CRC) was severely affected by the changes implemented during the pandemic, and this resulted in delayed elective presentation, increased emergency presentation, reduced screening and delayed definitive therapy. This review was conducted to analyze the impact of the coronavirus disease 2019 (COVID-19) pandemic on management of CRC and to identify the changes made in order to adapt to the pandemic. We performed a literature search in PubMed, Medline, Index Medicus, EMBASE, SCOPUS, *Reference Citation Analysis* (https://www.referencecitationanalysis.com/) and Google Scholar using the following keywords in various combinations: Colorectal cancer, elective surgery, emergency surgery, stage upgrading, screening, surveillance and the COVID-19 pandemic. Only studies published in English were included. To curtail the spread of COVID-19 infection, there were modifications made in the management of CRC. Screening was limited to high risk individuals, and the screening tests of choice during the pandemic were fecal occult blood test, fecal immunochemical test and stool DNA testing. The use of capsule colonoscopy and open access colonoscopy was also encouraged. Blood-based tests like serum methylated septin 9 were also encouraged for screening of CRC during the pandemic. The presentation of CRC was also affected by the pandemic with more patients presenting with emergencies like obstruction and perforation. Stage migration was also observed during the pandemic with more patients presenting with more advanced tumors. The operative therapy of CRC was altered by the pandemic as more emergencies surgeries were done, which may require exteriorization by stoma. This was to reduce the morbidity associated with anastomosis and encourage early discharge from the hospital. There was also an initial reduction in laparoscopic surgical procedures due to the fear of aerosols and COVID-19 infection. As we gradually come out of the pandemic, we should remember the lessons learned and continue to apply them even after the pandemic passes.

**Key Words:** COVID-19 pandemic; Colorectal cancer; Screening; Surveillance; Stage upgrading; Elective surgery; Emergency surgery

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Akbulut S, Hargura AS, Garzali IU, Aloun A, Colak C. Clinical presentation, management, screening and surveillance for colorectal cancer during the COVID-19 pandemic. *World J Clin Cases* 2022; 10(26): 9228-9240

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i26/9228.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i26.9228

**Core Tip:** Management and screening of colorectal cancer was severely affected by the changes implemented during the coronavirus disease 2019 (COVID-19) pandemic. These approaches resulted in delayed elective presentation, increased emergency presentation, reduced screening and delayed definitive therapy. Though the management of colorectal cancer did not adversely change during the pandemic, modifications of existing guidelines were proposed to minimize the risk of COVID-19 spread while not compromising oncological care and outcome. This review was conducted to analyze the impact of the COVID-19 pandemic on the management of colorectal cancer and to identify the changes made to adapt to the COVID-19 pandemic.

**INTRODUCTION**

The coronavirus disease 2019 (COVID-19) pandemic has altered the lives of people around the world, with a significant death toll in addition to global social, political and economic impact. The rapid spread of the virus has overwhelmed the global healthcare system capacity and impacted the management of patients with cancer and other chronic diseases[1,2]. It was declared a pandemic by the World Health Organization (WHO) in March 2020. Though the case fatality rate was reported as 2.2% in December 2020, there were 509 million infections reported globally with 6.23 million deaths across the globe according to the WHO COVID-19 dashboard as of April 27, 2022[3].

In response to the pandemic, there were global policy decisions like lockdown and stay at home orders that were aimed at preventing the spread of the virus. Unfortunately, these decisions resulted in the inability of patients with chronic diseases to access healthcare[4-6]. There was also redistribution of both human and material resources in the hospital setting to tackle the pandemic. This resulted in suspension or drastic reduction of all non-essential services, cancer care inclusive. The suspension of non-essential services was also aimed at preventing hospital acquired COVID-19 infections among patients presenting to the hospital[4-9].

Epidemiologically, colorectal cancer (CRC) is the third most common cancer in men and second in women. CRC is also the third most common cause of cancer-related deaths across the globe[10]. A malignancy of such incidence and mortality significance, with projected worldwide incidence of 2.5 million new cases by 2030[11,12], should be managed without much delay even in the face of a pandemic. But, management of CRC was severely affected by the changes implemented during the pandemic, and this resulted in delayed elective presentation, increased emergency presentation, reduced screening and delayed definitive therapy[6,8,13-18].

This review was conducted to analyze the impact of the COVID-19 pandemic on management of colon and rectal cancers and to identify the changes made in order to adapt to the pandemic.

**METHODS**

A literature search was conducted by three independent researchers. The keywords used for the search were “Colorectal cancer,” “Elective surgery,” “Emergency surgery,” “Stage upgrading,” “Screening,” “Surveillance” and “COVID-19 pandemic.” The keywords were combined using Boolean logic, and the search was conducted in PubMed, Medline, Index Medicus, EMBASE, Scopus, *Reference Citation Analysis* (https://www.referencecitationanalysis.com/) and Google Scholar. Only studies published in English were included. Related articles and reference list were also searched manually to avoid omission. The titles of the studies were screened, and the abstracts were evaluated for inclusion. Only full, original articles written in English were selected. National, regional and international guidelines were also included in the review. Owing to the nature of studies, low in volume and mostly retrospective or reviews, the authors opted to present a narrative review format rather than systematic review and meta-analysis.

**SCREENING AND SURVEILLANCE FOR COLORECTAL CANCER**

Screening is aimed at detecting colon and/or rectal cancers before the appearance of clinical sign and symptoms[19,20].

***Screening before the COVID-19 pandemic***

The recommended screening timeline depends on the risk level of the patients[7,20-25]. For people with no risk factors, screening starts at age 50-years-old. People with a close relative (parent or sibling) with colorectal cancer or polyps will start screening at age 40-years-old or at 10 years before the youngest age at which a relative was diagnosed[7,20-27]. These patients will often undergo screening every 5 years, even if their test is normal. Less common types of inherited colon cancer (hereditary non-polyposis colon cancer and familial adenomatous polyposis) may require more frequent screening, beginning at a much earlier age[7,20-27]. There are various methods of screening as described below.

**Fecal-based tests:** Most precancerous lesions bleed intermittently. So detection of occult blood in the feces may herald the presence of a lesion in the colon or rectum[28-30]. Currently, three types of stool tests are approved for screening of colorectal cancer:

**Guaiac fecal occult blood test:** Guaiacfecal occult blood testuses a chemical to detect heme, a component of the blood protein hemoglobin. Because guaiacfecal occult blood test can also detect heme in some foods (for example, red meat), people must avoid certain foods before having this test. It is supposed to be repeated annually[6,8,13,15,28-30].

**Fecal immunochemical (or immunohistochemical) test:** Fecal immunochemical (or immunohistochemical) test (FIT), also known as immunochemical fecal occult blood test uses antibodies to detect hemoglobin protein specifically. Dietary restrictions are typically not required for FIT. It is more sensitive that guaic based tests, and it should also be repeated annually[6,8,13,15,28-31].

**Multitargeted stool DNA testing:** Multitargeted stool DNA testing (also known as FIT-DNA) detects hemoglobin, along with certain DNA biomarkers. The DNA comes from cells in the lining of the colon and rectum that are shed and collect in stool as it passes through the large intestine and rectum. It should be repeated every 3 years[6,8,13,15,20,28-30,32,33].

**Blood-based tests:** A blood-based test assessing methylated septin 9 has been approved for CRC screening in individuals who refuse other CRC screening methods[34-38]. Initial studies reported a sensitivity of 48% for CRC detection and 11% for advanced adenoma detection. However, with enhancements in the test assay, a sensitivity of 62% and a specificity of 90% has been reported[34-38].

Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 have been investigated as a blood-based screening test for CRC, but their sensitivity and specificity were low, and they were not considered appropriate as screening tools[39-41]. The sensitivity of CEA was 65%-74%, while that of carbohydrate antigen 19-9 was 26%-48%. There were attempts to combine the two biomarkers for screening of CRC, but the evidence was not sufficient for guideline related recommendations[39-42].

**Direct visualization tests:** Direct visualization of the large bowel can also be utilized as a screening test. Flexible sigmoidoscopy allows direct evaluation of the left side of the colon. If adenomas are found, referral for a colonoscopy is required. It should be repeated every 5 years[20,23,43]. Colonoscopy is a screening, diagnostic and therapeutic procedure. It can detect cancers and precursor polyps. It is repeated every 10 years[20,23,43]. Capsule colonoscopy is a painless procedure using a pill camera to view the entire colon and rectum[27,44].Computed tomography colonography has been shown to have comparable sensitivity and specificity as colonoscopy but lacks the tissue sampling advantage of the colonoscopy[20,23,43].

***Screening during the COVID-19 pandemic***

At the onset of the pandemic, the policies aimed at reducing the spread of the virus also resulted in decreased access to screening for CRC. This was the direct result of decreased referrals from general practitioners, cessation of most aerosol generating procedures (colonoscopy inclusive) and redistribution of healthcare personnel to tackle the emergencies[7,9,10,21-25,45,46]. This has resulted in delays at scheduled access to CRC screening. Estimation models suggest that a moderate 7-12 mo screening delay will cause a significant increase in advanced cancers at detection (from 26% to 29%). This may be increased up to 33% in case of more than 12 mo delay[7,9,10,21-25,45-49].

In an effort to mitigate this, some modification for the screening protocol was proposed. Shaukat *et al*[43,50] proposed the use of FIT as a screening tool and reservation colonoscopy only for those in which FIT is positive. Fecal immunochemical test is a good option as it is noninvasive, non-aerosol generating and can be performed at home. The use of FIT-DNA was proposed by Kadakuntla *et al*[25] It has similar advantages to FIT with the added advantage of increased sensitivity to CRC and precancerous lesions.

Sulbaran *et al*[27] proposed the use of capsule colonoscopy as a screening tool during the COVID-19 pandemic. They found that the diagnostic performance of capsule colonoscopy was similar to that of conventional colonoscopy. However, the lack of the ability to biopsy the detected lesion is a disadvantage.

One of the challenges faced with the use of colonoscopy as a screening tool is the need for preprocedural evaluation by a specialist. This may require multiple hospital visits and may expose the patient to the risk of COVID-19 infection. To reduce this risk, open access colonoscopy was proposed as a screening tool[25,51,52]. This is a service that allows patients to schedule colonoscopies without a preprocedure evaluation by a gastroenterologist. It is a viable solution for addressing the delay in colonoscopy screening, as it allows for navigating the reallocation of gastrointestinal services in the setting of COVID-19. It is convenient for the patient and hospital as it allows patients to bypass a preprocedural specialist visit[25,51,52]. Because of variation in availability of the screening tools mentioned vis a vis the difference in economic situations in different countries, there is a need for clinicians in different countries to individualize the screening tools during the pandemic focusing on the ones readily available in their practice.

***Surveillance before the COVID-19 pandemic***

People who have precancerous polyps completely removed should have a colonoscopy every 3 years to 5 years, depending on the size, type and number of polyps found. The exam interval will usually depend upon the type of the growth removed.  If a polyp is not completely removed by colonoscopy or surgery, another colonoscopy should be done in 3 to 6 mo[20,53].

Most colorectal cancer patients should have a colonoscopy within 1 year of the removal of the cancer. If the whole colon could not be examined prior to surgery, then colonoscopy should be done within 3 mo to 6 mo. If this colonoscopy is normal, then colonoscopy should be done every 3 years to 5 years. Serum CEA can also be used for post treatment surveillance to detect early recurrence[20,53,54]. Patients with ulcerative colitis or Crohn’s disease for 8 or more years should have a colonoscopy with multiple biopsies every 1 year to 2 years[20,53,54].

***Surveillance during the COVID-19 pandemic***

The association of COVID-19 infection with elevation resulted in unreliability of the biomarker for surveillance of CRC during the COVID-19 pandemic. Social distancing and lockdown measures made access to colonoscopy difficult during the pandemic, and the use of open access colonoscopy and capsule colonoscopy in surveillance of CRC was encouraged[25,27,33,50,55].

**CLINICAL PRESENTATION OF COLORECTAL CANCER**

***Clinical presentation before the COVID-19 pandemic***

Initial symptoms experienced by patients are mostly not specific to CRC. The main symptoms detected in the majority of symptomatic patients are change in bowel habit, hematochezia, rectal fullness and abdominal pain[46,56-59]. Some advanced CRC patients can present as an emergency with intestinal obstruction or peritonitis from perforation of the tumor with no prior symptoms suggestive of CRC. This presentation creates a need for emergency surgery with quite high rates of mortality and morbidity. Emergency presentation is reported to occur in about 20%-30% of CRC with most of these emergencies presenting as acute on chronic intestinal obstruction[46,56-61].

Moghadamyeghaneh *et al*[18] reported that the stage of CRC at presentation depends on the age of the patients, with younger patients having more advanced disease. However, about 21.3% of patients present in stage I, 29.4% present in stage II, 31.7% present in stage III, while 17.6% of patients present in stage IV.

***Clinical presentation during the COVID-19 pandemic***

The clinical presentation was significantly affected by COVID-19. Meijer *et al*[62] reported a reduction of patients presenting with stage I and stage II CRC from 29.5% and 26.6% to 20.0% and 25.5%, respectively, after the onset of COVID-19 pandemic. They also noticed an increase of patients with stage III and stage IV from 22.2% and 19.0% to 26.8% and 26.2%, respectively[16,62]. These changes were attributed to the delays in screening and diagnosis of CRC that was caused by the COVID-19 pandemic[17,55,62]. The mode of presentation was also affected by the pandemic as Shinkwin *et al*[59] reported an increase in emergency presentation from 28.6% to 36.0%. The increased emergency presentation was also associated with increased morbidity and mortality[14,16,18,62].

**DIAGNOSIS OF COLORECTAL CANCER**

In symptomatic patients or patients who have positive screening results, further work-up is needed to diagnose, stage and plan the treatment. Colonoscopy remains the gold standard for the initial assessment and tissue diagnosis of CRC because it has the highest sensitivity and specificity while also offering the possibility of histopathological diagnosis[63,64]. It is therefore the initial step in the diagnosis of CRC. The entire colon should be assessed, and in cases where this is not possible due to obstruction it is recommended that it should be done within 3-6 mo of intervention to relieve the obstruction[63,64]. Computed tomography of the pelvis, abdomen and chest is also needed to stage the disease by assessment of locoregional and distant metastasis[63,64].

For rectal cancer, magnetic resonance imaging (MRI) of the pelvis is also needed to better characterize the T stage and locoregional extent of the disease[63-65]. Endoscopic rectal ultrasound, though superior to pelvic MRI in assessment of T stage, does not assess the disease relationship to the pelvic wall and adjacent organ invasion. Combined with limited availability and expertise required for endoscopic rectal ultrasound, MRI has become the preferred modality in assessing the rectum cancer. Positron emission tomography scan, though useful in assessment of disease recurrence, has no role in initial assessment and diagnosis of colorectal cancer[63-65].

The pandemic forced clinicians to make some modification like skipping endoscopic rectal ultrasound due to its invasive nature and increased risk for COVID-19 infection[40,55,62-66]. CEA levels should also be measured at presentation for adjunct diagnostic, prognostic and follow-up purposes.

**MANAGEMENT OF COLORECTAL CANCER**

***Management of colorectal cancer before the COVID-19 pandemic***

The management of CRC is multidisciplinary involving surgery, radiotherapy, chemotherapy, targeted therapy and even immunotherapy in selected cases[65]. Despite the histopathologic similarities of the CRC, there is a significant difference in the management approaches between colon and rectal cancers. Radiotherapy that forms a crucial component of rectal cancer has little relevance in colon cancer, whereas neoadjuvant therapy that is also a component of stage II or III rectal cancer is generally not indicated in colon cancer[63,65-67].

**Endoscopic approach:** There is an increase in the diagnosis of lesions at this stage with improved and guided screening of CRC. For early T1 lesions, even with submucosal involvement, advances in endoscopic interventions mean these lesions can be adequately treated with polypectomy, endoscopic mucosal or submucosal resections[68-70]. Endoscopic mucosal resections and endoscopic submucosal resections are indicated in lesions with suspicious characteristics based on mucosal pit patterns, polyp morphology and other endoscopic aspects of colorectal cancers[68-70]. These procedures are both safe and less expensive than surgery[68-70]. In most of these cases histopathological assessment reveals adequate margins, and no further management is needed[68-70]. Close, guideline-based surveillance using the aforementioned screening tools is required.

Endoscopic stenting can also be used to alleviate obstruction symptoms especially in left colon and rectosigmoid tumors. However, the decision for stenting should be multidisciplinary as stenting can limit the later use of targeted therapy such as anti-vascular endothelial growth factor due to the risk of perforation[65].

**Surgical treatment:** Surgery remains the cornerstone of curative intent CRC treatment. It is the definitive curative option for all stage I, II and III CRC and for stage IV disease where indicated either as palliative or curative intent after systemic therapy[63,65].

The surgery can be performed open, laparoscopic or by use of robotic surgery. The surgical procedure performed must be anatomical, oncologically sound and ensure an R0 resection with safe margins. Total mesocolic or mesorectal excisions are now well-defined procedures that guarantee safety of margins (proximal, distal or radial) and adequate lymphadenectomy to further histopathologically stage the disease or achieve better survival outcomes[71,72].

The surgical procedures done for colorectal cancers are right hemicolectomy, left hemicolectomy, anterior and low anterior resections and abdominoperineal resections. Transverse colectomy, though a viable option for transverse colon tumors, poses the risk of inadequate oncologically sound resection due to the nature of the vascular supply to the transverse colon. Therefore, some surgeons advocate for extended left or right colectomy in the management of transverse colon tumors[65,71,72].

Lymphadenectomy, the extent and number of nodes dissected or positive, is an important factor in staging and prognostication of cancer. When done properly, total mesocolic or mesorectal excision ensures adequate nodal dissection but extensive node dissection has not been shown to confer any oncological benefit while posing increased morbidity risks[65,71,72].

For the subset of emergency cases, either obstruction or perforation, surgery is needed to address the emergency and treat the cancer in certain cases. The emergency procedures range from diversion colostomy for advanced disease to Hartmann procedure or resection with anastomosis in resectable disease. The choice of the procedure is guided by the stage of the disease, extent of the complication and the hemodynamic status of the patient[63,65,71-73].

For patients who received neoadjuvant chemoradiation, the timing to surgery is generally 8-10 wk in order to maximize the benefits of chemoradiation and reduce postoperative morbidity[65].

**Radiotherapy:** Benefits of preoperative radiotherapy in reducing local recurrence of rectal cancer have been proven by several studies[74,75]. The clinical stage of the disease and the quality of the subsequent surgery play an important role in augmenting the benefits of radiotherapy in local disease control. Proper MRI staging to maximize radiotherapy benefits and oncologically sound surgical procedure cannot be over emphasized[74,75].

In rectal cancer, long course chemoradiation with fluoropyrimidine-based chemotherapy as radiation sensitizer is the mainstay of stage II and III disease management. This regimen achieves downsizing in most patients and complete response in 15%-20% of cases. There is also the option of short radiotherapy sessions (5 × 5 gray) followed by surgery either immediately or after a 4-8 wk delay to maximize the downsizing effect or to assess the nature of the disease in that window[74,76].

In cases of complete clinical response, watch and wait has been proposed as an alternative in a subset of patients but with close surveillance. Though there are worries of oncological safety of such an approach, there is data that supports the strategy in a subset of patients with sustained complete oncological response[65].

Driven by surgical complexity, morbidity and sometimes the life-altering nature of surgery for rectal cancer, there is a trend towards application of radiotherapy for early rectal cancer as an alternative to surgery. The approach has been shown to achieve 50%-60% rectal preservation but poses the problem of overtreatment for the patients who ultimately require rectal surgery[29,77,78].

**Systemic chemotherapy:** Fluoropyrimidine-based adjuvant chemotherapy has been shown to improve survival in stage III and high risk stage II patients[65]. The subset of stage II colon cancer patients who benefit from adjuvant therapy are T4 lesions, presence of perforation or obstruction, poor differentiation features, presence of lymphovascular invasion and where less than 12 lymph nodes were harvested[57,63,65,79]. In addition to the cytotoxic agents, biologics such as anti-vascular endothelial growth factor and anti-epidermal growth factor receptor, targeted immunotherapy and novel salvage therapy drugs such as regorafenib are currently in use as adjuvant alternative[65].

Tumor characteristics, such as microsatellite instability, RAS and RAF mutations and BRAF-V600E, do not only have prognostic value but guide the need and choice of the chemotherapy agent[65]. Therefore, targeted therapy of biologics such as anti-vascular endothelial growth factor bevacizumab are added to the fluoropymidine-based adjuvant therapy where indicated based of the tumor-specific mutations and patient factors[65].

There are certain specific features of the disease to consider such as proven inefficiency of fluoropyrimidines in high microsatellite instability disease and lack of benefit in anti-epidermal growth factor receptor use for right-sided colon cancers. Venook *et al*[80] showed a staggering significant difference in survival benefits of 16.4 mo for right-sided against 37.5 mo for the left-sided tumor location in the use of cetuximumab in patients with metastatic colorectal cancer. The duration of chemotherapy for colorectal cancer has traditionally been 6 mo. However, International Duration Evaluation of Adjuvant Chemotherapy Collaboration, drawing on six randomized phase 3 trials, showed that limiting the adjuvant period to 3 mo does not impair the efficacy of the treatment and reduces the cumulative toxicity, especially for non-T4, non-N2 stage III cancers[81].

For rectal cancer, systemic therapy is a component of the neoadjuvant concurrent chemoradiotherapy and as adjuvant therapy but with an emerging trend towards total neoadjuvant therapy for rectal cancer[65].

Systemic therapy is also the mainstay for metastatic stage IV colorectal cancer, both for treatment intent and symptom palliation. Locoregional therapy for oligometastatic disease can be added to the systemic therapy to improve survival and success of surgical intervention[65].

***Management of colorectal cancer during the COVID-19 pandemic***

The general management of diagnosed and staged CRC has not changed much during the pandemic. However, modifications based on existing trends have been proposed to minimize risk of COVID-19 spread.

**Endoscopic procedure:** During the COVID-19 pandemic restrictions there were a significant drop in elective procedures such as screening and diagnostic colonoscopies. Some studies reported a 50% drop in screening and diagnostic colonoscopy procedures[9,10,21,24,45,47,49,82]. This translates to a considerable drop in early diagnosis and endoscopic procedure for T1 lesions amenable to endoscopic resections such as polypectomy, endoscopic mucosal resections or endoscopic submucosal dissection[9,10,21,24,45,47,49,82].

However, where diagnosis has been made these procedures should be done as they avert need for more invasive surgery but with risk analysis as endoscopic intervention fall under the “medium priority” subset as per the European Society for Medical Oncology guide modification for the pandemic by Vecchione *et al*[83].

**Surgical management:** Surgery is a major therapeutic option with proven survival benefit in early CRC. Surgery is the only definitive treatment available for emergency presentation such as perforation or obstruction. Surgery for high-risk cases such as perforation or obstruction should not be postponed even during the pandemic. However, to reduce risk of infection and time-sensitive morbidities, acceptable procedures such as Hartmann procedures or diversion colostomies should be preferred[9,10,17,21,45,46,48,55,58,62,67,84-86].

Elective surgery for the procedure is classified as medium priority and can be postponed but not beyond 6 wk due to the risk of cancer progression and impact of survival. Reconstructive procedures such as ostomy reversal are low priority and can wait until such time when appropriate. Prophylactic colon resections for familial syndromes can also be postponed as they are low priority[9,10,17,21,45,46,48,55,58,62,67,84-86].

For patients who with complete clinical response after neoadjuvant therapy watch and wait approach can be adopted for all patients to avoid the risk of infection and postoperative morbidities[9,10,17,21,45,46,48,55,58,62,67,84-86].

The clinician should bear in mind that the delays of surgical procedures might induce psychological distress and may necessitate the need for psychological support *via* telemedicine[83].

**Radiotherapy:** Radiotherapy is a vital component of neoadjuvant chemoradiation for rectal cancer as it helps reduce the risk of disease recurrence especially in patients where the radial margin is threatened. In stage II and III patients, though not indicated in all, short-term radiotherapy (5 × 5 gray) should be considered in all during the pandemic. The response can then be assessed at 8 wk with a chance to extend the waiting period to 12-16 wk if there is a good response. The total neoadjuvant treatment approach will work well in the pandemic era as the length of the treatment and the subsequent assessment period gives the patients and team without compromising on the oncological outcomes[87].

**Systemic chemotherapy:** Because chemoradiation poses the increased risk of infection and related complications due to immunosuppression, measures such as use of oral capecitabine for microsatellite stable stage III and high-risk stage II disease can help mitigate the risks compared to stage IV 5-fluorouracil that requires hospitalization[10]. Since 5-fluorouracil has been shown to be ineffective or even detrimental in high microsatellite instability CRC, microsatellite instability testing should be recommended to avoid ineffective administration therapy, potential side effects and unnecessary exposure to the risk of COVID-19 infection[10].

To minimize the risk of infection due to prolonged immunosuppression caused by standard 6 mo therapy, the non-inferior 3 mo option can be universally adopted especially for a subgroup of patients (stage II and low-risk stage III)[81].

Using chemoradiotherapy where it has been shown to have absolute benefit, dose adjustments and prophylactic granulocyte colony-stimulating factor to reduce grade 3-4 toxicities that require hospitalizations are some of the measures that reduce the risk of exposure and severe COVID-19 disease for the patients[10].

***Treatment of colorectal cancer emergencies during the COVID-19 pandemic***

A significant number of patients may require emergency intervention for emergency presentations such as obstruction and perforation. Such patients tend to be older with more advanced tumors[73]. These factors contribute to prolonged recovery time and a relatively poor prognosis. The main aim of treatment is to minimize trauma to the patients, reduce hospital stay and to prevent COVID-19 infection. Respiratory screening should be done before surgery to rule out COVID-19 infection[9,73,79,82,88]. Endoscopic colonic stenting using self-expanding metallic stents should first be attempted in patients with obstruction. A successful endoscopic colonic stenting relieves obstruction, which in turn allows commencement of neoadjuvant chemotherapy that may downstage the tumor[9,73,79,82,88]. In patients with low rectal tumor, stenting should be avoided as it may cause incontinence and tenesmus[9].

Operative treatment is still required for patients with intestinal obstruction refractory to endoscopic therapy and for patients with malignant bowel perforation with peritonitis. The main aim of the operative treatment is to resolve the emergency situation. This can be achieved by creating a stoma and diverting fecal flow[66]. Definitive therapy has been associated with prolonged hospital stay and increased risk of COVID-19 infection. However, Ren *et al*[9], recommended definitive surgery in selected patients.

In patients with perforation and peritonitis, irrigation of the peritoneal cavity and limited segmental resection of the perforated segment and proximal stoma are recommended[66]. Laparoscopic approach to surgical intervention has been encouraged by some surgeons as this is associated with less surgical trauma and encourages early discharge[9]. However, at the initial stage of the pandemic, there was reduction in laparoscopy given the uncertainty of airborne and aerosol transmission risks[89,90].

Emergency surgeries should be performed in the designated hospital and operated in a negative pressure (-5 Pa) operating room. The team members should use enhanced protection including wearing medical cups, N95 or higher-level respirators, medical coverall, eye shield, surgical latex gloves, disposable operating coat, protective hood, waterproof shoe covers and disposable shoe covers[89-93]. Anesthesiologists should wear an additional disposable medical face shield as a protection from coughed droplets during trachea intubation and extubating. Treatment meticulous dissection is advised to reduce splash of bodily fluids during surgery[89-92].

**CONCLUSION**

The COVID-19 pandemic was a reminder of how adaptable we really are. The adaptability was due to our ability to quickly learn the nature of the disease and to quickly modify our practice to reduce its spread. While we are coming out of the COVID-19 pandemic, there is a need to remember the lessons learned.

***The need for disaster plan***

Hospitals should have a detailed disaster plan that includes the following[94,95]: What areas of the hospital to expand to and in what order; how to increase the ability to care for incoming patients; and how to gain immediate access to additional staff.

***Expedited publication of research***

Research during the COVID-19 pandemic have been disseminated promptly, with many researchers using the medrvix and biorvix preprint servers to publish their work. With increased publication comes increased collaboration among different groups aimed at finding an appropriate solution to the pandemic and to see how best to treat chronic diseases not relating to the COVID-19 pandemic[94,95].

***Telemedicine and role of artificial intelligence***

The pandemic has proven that digital health can be an integrated part of public health[96,97]. This was obvious when social distancing became a requirement. Artificial intelligence helped in combatting COVID-19 and other diseases like CRC. Artificial intelligence has been a very important tool in screening, diagnosing and treating CRC. Telemedicine has played a critical role in the management of CRC during the COVID-19 pandemic. It ensured continuous access to healthcare by the patients, it reduced exposure for staff and patients, it ensured preservation of personal protective equipment, and it reduced demand on facilities[96,97].

***Stage migration may occur in delay of screening procedures***

With the documented reductions in screening measures and treatment delays occasioned by COVID-19 measures, the medical community should anticipate a general shift in colorectal cancer stage, a negative impact on survival and recurrence of the disease[10,16,48,49,55,58,91,92]. Therefore, there will need to be vigilant and aggressive in screening and prioritizing oncology patients as the world gears towards post pandemic normalization of the health systems albeit some reported surges in COVID-19 cases, especially in Southeast Asia[10,16,48,49,55,58,91,92].

***Increased use of neoadjuvant therapy***

Due to the aerosol generating nature of surgical procedures, there was an increased use of neoadjuvant therapy especially in tumors that showed significant clinical response. The impact of this increased use on prognosis needs to be assessed over time.

**REFERENCES**

1 **Cao Y**, Hiyoshi A, Montgomery S. COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. *BMJ Open* 2020; **10**: e043560 [PMID: 33148769 DOI: 10.1136/bmjopen-2020-043560]

2 **Hasan MN**, Haider N, Stigler FL, Khan RA, McCoy D, Zumla A, Kock RA, Uddin MJ. The Global Case-Fatality Rate of COVID-19 Has Been Declining Since May 2020. *Am J Trop Med Hyg* 2021; **104**: 2176-2184 [PMID: 33882025 DOI: 10.4269/ajtmh.20-1496]

3 **World Health Organization.** WHO Coronavirus (COVID-19) Dashboard Overview. July 11, 2022. [cited 1 May 2022]. Available from: https://covid19.who.int/

4 **Cirrincione L,** Plescia F, Ledda C, Rapisarda V, Martorana D, Moldovan RE, Theodoridou K, Cannizzaro E. COVID-19 pandemic: Prevention and protection measures to be adopted at the workplace. *Sustainability* 2020; **12**: 3603 [DOI: 10.3390/su12093603]

5 **Dadras O**, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, Pashaei Z, Mirzapour P, Fakhfouri A, Zargari G, Saeidi S, Mojdeganlou H, Badri H, Qaderi K, Behnezhad F, Mehraeen E. Effects of COVID-19 prevention procedures on other common infections: a systematic review. *Eur J Med Res* 2021; **26**: 67 [PMID: 34217366 DOI: 10.1186/s40001-021-00539-1]

6 **Jen GH**, Yen AM, Hsu CY, Chiu HM, Chen SL, Chen TH. Modelling the impacts of COVID-19 pandemic on the quality of population-based colorectal cancer screening. *Prev Med* 2021; **151**: 106597 [PMID: 34217416 DOI: 10.1016/j.ypmed.2021.106597]

7 **Alkatout I**, Biebl M, Momenimovahed Z, Giovannucci E, Hadavandsiri F, Salehiniya H, Allahqoli L. Has COVID-19 Affected Cancer Screening Programs? A Systematic Review. *Front Oncol* 2021; **11**: 675038 [PMID: 34079764 DOI: 10.3389/fonc.2021.675038]

8 **Mazidimoradi A**, Tiznobaik A, Salehiniya H. Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: a Systematic Review. *J Gastrointest Cancer* 2021 [PMID: 34406626 DOI: 10.1007/s12029-021-00679-x]

9 **Ren X**, Chen B, Hong Y, Liu W, Jiang Q, Yang J, Qian Q, Jiang C. The challenges in colorectal cancer management during COVID-19 epidemic. *Ann Transl Med* 2020; **8**: 498 [PMID: 32395542 DOI: 10.21037/atm.2020.03.158]

10 **Alam W**, Bouferraa Y, Haibe Y, Mukherji D, Shamseddine A. Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. *Sci Prog* 2021; **104**: 368504211010626 [PMID: 33878982 DOI: 10.1177/00368504211010626]

11 **Arnold M**, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. *Gastroenterology* 2020; **159**: 335-349.e15 [PMID: 32247694 DOI: 10.1053/j.gastro.2020.02.068]

12 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

13 **American College of Surgeons**. COVID-19 Guidelines for Triage of Colorectal Cancer Patients. Available from: https://www.facs.org/for-medical-professionals/covid-19/clinical-guidance/elective-case/colorectal-cancer

14 **Ergün S,** Tunç E, Avcı T, Batur Ş, Kepil N, Uludağ SS, Özçelik MF. The Effect of the COVID-19 Pandemic on the Clinical and Pathological Stages of Colorectal Cancer Patients. *Turk J Colorectal Dis* 2022; **32**: 36-40 [DOI: 10.4274/tjcd.galenos.2021.2021-9-1]

15 **Harber I**, Zeidan D, Aslam MN. Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences. *Life (Basel)* 2021; **11** [PMID: 34947828 DOI: 10.3390/Life11121297]

16 **Liyanage ASD**, Gokul K, Babu BH, Ainsworth P. Stage migration of colorectal cancer during COVID-19 pandemic. *Br J Surg* 2020; **107**: e477 [PMID: 32876950 DOI: 10.1002/bjs.11936]

17 **Marshall JL,** Yarden RI, Weinberg BA. Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit. *Colorectal Cancer* 2020; **9**: CRC17 [DOI: 10.2217/crc-2020-0010]

18 **Moghadamyeghaneh Z**, Alizadeh RF, Phelan M, Carmichael JC, Mills S, Pigazzi A, Zell JA, Stamos MJ. Trends in colorectal cancer admissions and stage at presentation: impact of screening. *Surg Endosc* 2016; **30**: 3604-3610 [PMID: 26541735 DOI: 10.1007/s00464-015-4662-3]

19 **Hakama M**. Cancer screening for medical oncologists: definitions and aims. *Ann Oncol* 2002; **13 Suppl 4**: 185-188 [PMID: 12401688 DOI: 10.1093/annonc/mdf658]

20 **American Society of Colon and Rectal Surgeons**. Screening and Surveillance for Colorectal Cancer. 2022 Available from: https://fascrs.org/patients/diseases-and-conditions/a-z/screening-and-surveillance-for-colorectal-cancer

21 **Boyle JM**, Kuryba A, Blake HA, Aggarwal A, van der Meulen J, Walker K, Braun M, Fearnhead N. The impact of the first peak of the COVID-19 pandemic on colorectal cancer services in England and Wales: A national survey. *Colorectal Dis* 2021; **23**: 1733-1744 [PMID: 33686679 DOI: 10.1111/codi.15622]

22 **D'Ovidio V**, Lucidi C, Bruno G, Lisi D, Miglioresi L, Bazuro ME. Impact of COVID-19 Pandemic on Colorectal Cancer Screening Program. *Clin Colorectal Cancer* 2021; **20**: e5-e11 [PMID: 32868231 DOI: 10.1016/j.clcc.2020.07.006]

23 **Dekker E**, Chiu HM, Lansdorp-Vogelaar I; WEO Colorectal Cancer Screening Committee. Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. *Gastroenterology* 2020; **159**: 1998-2003 [PMID: 32966824 DOI: 10.1053/j.gastro.2020.09.018]

24 **Issaka RB**, Taylor P, Baxi A, Inadomi JM, Ramsey SD, Roth J. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. *JAMA Netw Open* 2021; **4**: e216454 [PMID: 33843997 DOI: 10.1001/jamanetworkopen.2021.6454]

25 **Kadakuntla A**, Wang T, Medgyesy K, Rrapi E, Litynski J, Adynski G, Tadros M. Colorectal cancer screening in the COVID-19 era. *World J Gastrointest Oncol* 2021; **13**: 238-251 [PMID: 33889276 DOI: 10.4251/wjgo.v13.i4.238]

26 **Kelkar AH**, Zhao J, Wang S, Cogle CR. Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System. *Healthcare (Basel)* 2022; **10** [PMID: 35206878 DOI: 10.3390/healthcare10020264]

27 **Sulbaran M**, Bustamante-Lopez L, Bernardo W, Sakai CM, Sakai P, Nahas S, Moura EGH. Systematic review and meta-analysis of colon capsule endoscopy accuracy for colorectal cancer screening. An alternative during the Covid-19 pandemic? *J Med Screen* 2022: 9691413221074803 [PMID: 35068246 DOI: 10.1177/09691413221074803]

28 **Ebner DW**, Kisiel JB. Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy. *Curr Gastroenterol Rep* 2020; **22**: 32 [PMID: 32494878 DOI: 10.1007/s11894-020-00770-6]

29 **Lin JS**, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2021; **325**: 1978-1998 [PMID: 34003220 DOI: 10.1001/jama.2021.4417]

30 **Robertson DJ**, Imperiale TF. Stool Testing for Colorectal Cancer Screening. *Gastroenterology* 2015; **149**: 1286-1293 [PMID: 26033632 DOI: 10.1053/j.gastro.2015.05.045]

31 **Loveday C**, Sud A, Jones ME, Broggio J, Scott S, Gronthound F, Torr B, Garrett A, Nicol DL, Jhanji S, Boyce SA, Williams M, Barry C, Riboli E, Kipps E, McFerran E, Muller DC, Lyratzopoulos G, Lawler M, Abulafi M, Houlston RS, Turnbull C. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. *Gut* 2021; **70**: 1053-1060 [PMID: 32855306 DOI: 10.1136/gutjnl-2020-321650]

32 **Myint A**, Roh L, Yang L, Connolly L, Esrailian E, May FP. Noninvasive Colorectal Cancer Screening Tests Help Close Screening Gaps During Coronavirus Disease 2019 Pandemic. *Gastroenterology* 2021; **161**: 712-714.e1 [PMID: 33865840 DOI: 10.1053/j.gastro.2021.04.026]

33 **Sundaram S**, Olson S, Sharma P, Rajendra S. A Review of the Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: Implications and Solutions. *Pathogens* 2021; **10** [PMID: 34832663 DOI: 10.3390/pathogens10111508]

34 **Church TR**, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut* 2014; **63**: 317-325 [PMID: 23408352 DOI: 10.1136/gutjnl-2012-304149]

35 **Nian J**, Sun X, Ming S, Yan C, Ma Y, Feng Y, Yang L, Yu M, Zhang G, Wang X. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. *Clin Transl Gastroenterol* 2017; **8**: e216 [PMID: 28102859 DOI: 10.1038/ctg.2016.66]

36 **Parikh RB**, Prasad V. Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption? *JAMA* 2016; **315**: 2519-2520 [PMID: 27305625 DOI: 10.1001/jama.2016.7914]

37 **Song L**, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. *Sci Rep* 2017; **7**: 3032 [PMID: 28596563 DOI: 10.1038/s41598-017-03321-8]

38 **Wu D**, Zhou G, Jin P, Zhu J, Li S, Wu Q, Wang G, Sheng J, Wang J, Song L, Han X, Qian J. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. *J Mol Diagn* 2016; **18**: 535-545 [PMID: 27133379 DOI: 10.1016/j.jmoldx.2016.02.005]

39 **Kim NH**, Lee MY, Park JH, Park DI, Sohn CI, Choi K, Jung YS. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. *Yonsei Med J* 2017; **58**: 918-924 [PMID: 28792134 DOI: 10.3349/ymj.2017.58.5.918]

40 **Lakemeyer L**, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. *Diseases* 2021; **9** [PMID: 33802962 DOI: 10.3390/diseases9010021]

41 **Sekiguchi M**, Matsuda T. Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. *Sci Rep* 2020; **10**: 18202 [PMID: 33097814 DOI: 10.1038/s41598-020-75319-8]

42 **Yang C**, Wang J, Liu J, Huang S, Xiong B. Elevated carcinoembryonic antigen in patients with COVID-19 pneumonia. *J Cancer Res Clin Oncol* 2020; **146**: 3385-3388 [PMID: 32857179 DOI: 10.1007/s00432-020-03350-3]

43 **Shaukat A**, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. *Am J Gastroenterol* 2021; **116**: 458-479 [PMID: 33657038 DOI: 10.14309/ajg.0000000000001122]

44 **Rex DK**, Adler SN, Aisenberg J, Burch WC Jr, Carretero C, Chowers Y, Fein SA, Fern SE, Fernandez-Urien Sainz I, Fich A, Gal E, Horlander JC Sr, Isaacs KL, Kariv R, Lahat A, Leung WK, Malik PR, Morgan D, Papageorgiou N, Romeo DP, Shah SS, Waterman M. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. *Gastroenterology* 2015; **148**: 948-957.e2 [PMID: 25620668 DOI: 10.1053/j.gastro.2015.01.025]

45 **Balzora S**, Issaka RB, Anyane-Yeboa A, Gray DM 2nd, May FP. Impact of COVID-19 on colorectal cancer disparities and the way forward. *Gastrointest Endosc* 2020; **92**: 946-950 [PMID: 32574570 DOI: 10.1016/j.gie.2020.06.042]

46 **Ferahman S,** Donmez T, Surek A, Aydin H, Gumusoglu AY, Karabulut M. Effects of COVID-19 Outbreak on Emergency Surgeries for Occlusive Colorectal Cancers. *Turk J Colorectal Dis* 2020; **30**: 237-246 [DOI: 10.4274/tjcd.galenos.2020.2020-7-2]

47 **Lim JH**, Lee WY, Yun SH, Kim HC, Cho YB, Huh JW, Park YA, Shin JK. Has the COVID-19 Pandemic Caused Upshifting in Colorectal Cancer Stage? *Ann Coloproctol* 2021; **37**: 253-258 [PMID: 34376026 DOI: 10.3393/ac.2021.00269.0038]

48 **Morris EJA**, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J, Richards M, Spencer K, Emberson J, Hollings S, Curnow P, Gair D, Sebag-Montefiore D, Cunningham C, Rutter MD, Nicholson BD, Rashbass J, Landray M, Collins R, Casadei B, Baigent C. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. *Lancet Gastroenterol Hepatol* 2021; **6**: 199-208 [PMID: 33453763 DOI: 10.1016/S2468-1253(21)00005-4]

49 **Radulovic RS**, Cuk VV, Juloski JT, Arbutina DD, Krdžic ID, Milic LV, Kenic MV, Karamarkovic AR. Is Colorectal Cancer Stage Affected by COVID-19 Pandemic? *Chirurgia (Bucur)* 2021; **116**: 331-338 [PMID: 34191714 DOI: 10.21614/chirurgia.116.3.331]

50 **Shaukat A**, Church T. Colorectal cancer screening in the USA in the wake of COVID-19. *Lancet Gastroenterol Hepatol* 2020; **5**: 726-727 [PMID: 32569576 DOI: 10.1016/S2468-1253(20)30191-6]

51 **Grossi E**, Pace F. Guidelines for the Perplexed: How to Maximize Colonoscopy Efficiency During the COVID-19 Pandemic. *Dig Dis Sci* 2021; **66**: 2473-2474 [PMID: 33001345 DOI: 10.1007/s10620-020-06634-3]

52 **Xiao AH**, Chang SY, Stevoff CG, Komanduri S, Pandolfino JE, Keswani RN. Adoption of Multi-society Guidelines Facilitates Value-Based Reduction in Screening and Surveillance Colonoscopy Volume During COVID-19 Pandemic. *Dig Dis Sci* 2021; **66**: 2578-2584 [PMID: 32803460 DOI: 10.1007/s10620-020-06539-1]

53 **Liu SL**, Cheung WY. Role of surveillance imaging and endoscopy in colorectal cancer follow-up: Quality over quantity? *World J Gastroenterol* 2019; **25**: 59-68 [PMID: 30643358 DOI: 10.3748/wjg.v25.i1.59]

54 **Velenik V**. Post-treatment surveillance in colorectal cancer. *Radiol Oncol* 2010; **44**: 135-141 [PMID: 22933905 DOI: 10.2478/v10019-010-0018-8]

55 **Campos FG,** Fillmann HS. Potential impact of COVID-19 on colorectal disease management. *J Coloproctol (Rio J)* 2020; **40**: 196-201 [DOI: 10.1016/j.jcol.2020.06.002]

56 **Fisher SE,** Daniels IR. The Clinical Presentation of Colorectal Cancer. *Colorectal Cancer* 2008 [DOI: 10.1017/CBO9780511902468.002]

57 **Kumar S,** Kafle P, Patowary B, Belbase N, Agrawal S, Shrestha S, Maharjan N. Surgical outcome and clinical profile of emergency *vs* elective cases of colorectal cancer in college of medical sciences. *Nepal. J Coll Med Sci-Nepal* 2013; **9**: 25-30 [DOI: 10.3126/jcmsn.v9i2.9684]

58 **Mizuno R**, Ganeko R, Takeuchi G, Mimura K, Nakahara H, Hashimoto K, Hinami J, Shimomatsuya T, Kubota Y. The number of obstructive colorectal cancers in Japan has increased during the COVID-19 pandemic: A retrospective single-center cohort study. *Ann Med Surg (Lond)* 2020; **60**: 675-679 [PMID: 33282280 DOI: 10.1016/j.amsu.2020.11.087]

59 **Shinkwin M**, Silva L, Vogel I, Reeves N, Cornish J, Horwood J, Davies MM, Torkington J, Ansell J. COVID-19 and the emergency presentation of colorectal cancer. *Colorectal Dis* 2021; **23**: 2014-2019 [PMID: 33793063 DOI: 10.1111/codi.15662]

60 **Bayar B**, Yılmaz KB, Akıncı M, Şahin A, Kulaçoğlu H. An evaluation of treatment results of emergency versus elective surgery in colorectal cancer patients. *Ulus Cerrahi Derg* 2016; **32**: 11-17 [PMID: 26985154 DOI: 10.5152/UCD.2015.2969]

61 **Lavanchy JL**, Vaisnora L, Haltmeier T, Zlobec I, Brügger LE, Candinas D, Schnüriger B. Oncologic long-term outcomes of emergency versus elective resection for colorectal cancer. *Int J Colorectal Dis* 2019; **34**: 2091-2099 [PMID: 31709491 DOI: 10.1007/s00384-019-03426-8]

62 **Meijer J**, Elferink MAG, van Hoeve JC, Buijsen J, van Erning F, Nagtegaal ID, Tanis PJ, Vink GR, Wumkes ML, de Hingh IHJT, Siesling S; On-behalf-of-the-COVID-and-Cancer-NL Consortium. Impact of the COVID-19 Pandemic on Colorectal Cancer Care in the Netherlands: A Population-based Study. *Clin Colorectal Cancer* 2022 [PMID: 35346605 DOI: 10.1016/j.clcc.2022.02.005]

63 **Nakayama G**, Tanaka C, Kodera Y. Current Options for the Diagnosis, Staging and Therapeutic Management of Colorectal Cancer. *Gastrointest Tumors* 2013; **1**: 25-32 [PMID: 26674429 DOI: 10.1159/000354995]

64 **Sawicki T**, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers (Basel)* 2021; **13** [PMID: 33922197 DOI: 10.3390/cancers13092025]

65 **Dekker E**, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet* 2019; **394**: 1467-1480 [PMID: 31631858 DOI: 10.1016/S0140-6736(19)32319-0]

66 **Keramati MR**, Behboudi B, Ahmadi-Tafti SM, Kazemeini A, Keshvari A, Salahshour F, Aghili M, Alborzi F, Aletaha N, Babaei M, Bangash MN, Ebrahimi-Daryani N, Emami AH, Farhan F, Haddad P, Kalani M, Naseri A, Shahi F, Fazeli MS. Management of colon and rectal cancers during COVID-19 pandemic: A clinical guideline (TUMS-CRC-CoV19 Guideline). *Med J Islam Repub Iran* 2020; **34**: 128 [PMID: 33437724 DOI: 10.34171/mjiri.34.128]

67 **Pryor A.** SAGES AND EAES Recommendations Regarding Surgical Response to COVID-19 Crisis. SAGES, 2020 Available from: <https://www.sages.org/recommendations-surgical-response-covid-19/>

68 **Hayashi N**, Tanaka S, Hewett DG, Kaltenbach TR, Sano Y, Ponchon T, Saunders BP, Rex DK, Soetikno RM. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. *Gastrointest Endosc* 2013; **78**: 625-632 [PMID: 23910062 DOI: 10.1016/j.gie.2013.04.185]

69 **Lui TKL**, Wong KKY, Mak LLY, Ko MKL, Tsao SKK, Leung WK. Endoscopic prediction of deeply submucosal invasive carcinoma with use of artificial intelligence. *Endosc Int Open* 2019; **7**: E514-E520 [PMID: 31041367 DOI: 10.1055/a-0849-9548]

70 **Mann R**, Gajendran M, Umapathy C, Perisetti A, Goyal H, Saligram S, Echavarria J. Endoscopic Management of Complex Colorectal Polyps: Current Insights and Future Trends. *Front Med (Lausanne)* 2021; **8**: 728704 [PMID: 35127735 DOI: 10.3389/fmed.2021.728704]

71 **Lynch ML**, Brand MI. Preoperative evaluation and oncologic principles of colon cancer surgery. *Clin Colon Rectal Surg* 2005; **18**: 163-173 [PMID: 20011299 DOI: 10.1055/s-2005-916277]

72 **Rentsch M**, Schiergens T, Khandoga A, Werner J. Surgery for Colorectal Cancer - Trends, Developments, and Future Perspectives. *Visc Med* 2016; **32**: 184-191 [PMID: 27493946 DOI: 10.1159/000446490]

73 **Hogan J**, Samaha G, Burke J, Chang KH, Condon E, Waldron D, Coffey JC. Emergency presenting colon cancer is an independent predictor of adverse disease-free survival. *Int Surg* 2015; **100**: 77-86 [PMID: 25594643 DOI: 10.9738/INTSURG-D-13-00281.1]

74 **Ma B**, Gao P, Wang H, Xu Q, Song Y, Huang X, Sun J, Zhao J, Luo J, Sun Y, Wang Z. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. *Int J Cancer* 2017; **141**: 1052-1065 [PMID: 28560805 DOI: 10.1002/ijc.30805]

75 **Wang Y**, Shen L, Wan J, Zhang H, Wu R, Wang J, Wang Y, Xu Y, Cai S, Zhang Z, Xia F. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH). *BMC Cancer* 2022; **22**: 274 [PMID: 35291966 DOI: 10.1186/s12885-022-09348-z]

76 **Bisschop C**, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP. Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study. *Ann Surg Oncol* 2017; **24**: 2632-2638 [PMID: 28560600 DOI: 10.1245/s10434-017-5897-0]

77 **Rullier E**, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. *Lancet* 2017; **390**: 469-479 [PMID: 28601342 DOI: 10.1016/S0140-6736(17)31056-5]

78 **Ryan JE**, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. *Colorectal Dis* 2016; **18**: 234-246 [PMID: 26531759 DOI: 10.1111/codi.13207]

79 **Pisano M**, Zorcolo L, Merli C, Cimbanassi S, Poiasina E, Ceresoli M, Agresta F, Allievi N, Bellanova G, Coccolini F, Coy C, Fugazzola P, Martinez CA, Montori G, Paolillo C, Penachim TJ, Pereira B, Reis T, Restivo A, Rezende-Neto J, Sartelli M, Valentino M, Abu-Zidan FM, Ashkenazi I, Bala M, Chiara O, De' Angelis N, Deidda S, De Simone B, Di Saverio S, Finotti E, Kenji I, Moore E, Wexner S, Biffl W, Coimbra R, Guttadauro A, Leppäniemi A, Maier R, Magnone S, Mefire AC, Peitzmann A, Sakakushev B, Sugrue M, Viale P, Weber D, Kashuk J, Fraga GP, Kluger I, Catena F, Ansaloni L. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. *World J Emerg Surg* 2018; **13**: 36 [PMID: 30123315 DOI: 10.1186/s13017-018-0192-3]

80 **Venook AP**, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA* 2017; **317**: 2392-2401 [PMID: 28632865 DOI: 10.1001/jama.2017.7105]

81 **Grothey A**, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *N Engl J Med* 2018; **378**: 1177-1188 [PMID: 29590544 DOI: 10.1056/NEJMoa1713709]

82 **Mukherji R**, Marshall JL. Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic. *Curr Treat Options Oncol* 2021; **22**: 93 [PMID: 34424418 DOI: 10.1007/s11864-021-00888-3]

83 **Vecchione L**, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. *ESMO Open* 2020; **5** [PMID: 32457036 DOI: 10.1136/esmoopen-2020-000826]

84 **Uyan M**, Özdemir A, Kalcan S, Tomas K, Demiral G, Pergel A, Tarım İA. Effects of COVID-19 pandemic on colorectal cancer surgery. *Sao Paulo Med J* 2022; **140**: 244-249 [PMID: 34586288 DOI: 10.1590/1516-3180.2021.0357.R1.30062021]

85 **Williams E**, Kong JC, Singh P, Prabhakaran S, Warrier SK, Bell S. The impact of the COVID-19 pandemic on colorectal cancer diagnosis and management: a Binational Colorectal Cancer Audit study. *ANZ J Surg* 2021; **91**: 2091-2096 [PMID: 34235835 DOI: 10.1111/ans.17071]

86 **Xu Y**, Huang ZH, Zheng CZ, Li C, Zhang YQ, Guo TA, Liu FQ, Xu Y. The impact of COVID-19 pandemic on colorectal cancer patients: a single-center retrospective study. *BMC Gastroenterol* 2021; **21**: 185 [PMID: 33879095 DOI: 10.1186/s12876-021-01768-8]

87 **Akyol C,** Koç MA, Utkan G, Yıldız F, Kuzu MA. The COVID 19 pandemic and colorectal cancer: 5W1H-what should we do to whom, when, why, where and how. *Turk J Colorectal Dis* 2020; **30**: 67-75 [DOI: 10.4274/tjcd.galenos.2020.2020.4.11]

88 **Maertens V**, Stefan S, Rawlinson E, Ball C, Gibbs P, Mercer S, Khan JS. Emergency robotic colorectal surgery during COVID-19 pandemic: A retrospective case series study. *Laparosc Endosc Robot Surg* 2022; **5**: 57-60 [PMID: 35342848 DOI: 10.1016/j.lers.2022.03.001]

89 **Allaix ME**, Lo Secco G, Velluti F, De Paolis P, Arolfo S, Morino M. Colorectal surgery during the COVID-19 outbreak: do we need to change? *Updates Surg* 2021; **73**: 173-177 [PMID: 33387170 DOI: 10.1007/s13304-020-00947-8]

90 **Gao Y**, Xi H, Chen L. Emergency Surgery in Suspected COVID-19 Patients With Acute Abdomen: Case Series and Perspectives. *Ann Surg* 2020; **272**: e38-e39 [PMID: 32301807 DOI: 10.1097/SLA.0000000000003961]

91 **Amore Bonapasta S**, Santoni S, Cisano C. Emergency laparoscopic surgery during COVID-19: What can we do and how to do it safely. *J Trauma Acute Care Surg* 2020; **89**: 275-276 [PMID: 32404632 DOI: 10.1097/TA.0000000000002784]

92 **Athisayaraj T,** Beeby C, Catumbela R, Siddique R, Sebastian B, Mishra A. Impact of COVID 19 on elective and emergency colorectal cancer operations. *Colorectal Disease* 2021; **23**: 89

93 **Liu Z**, Zhang Y, Wang X, Zhang D, Diao D, Chandramohan K, Booth CM. Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. *Indian J Surg* 2020; **82**: 124-128 [PMID: 32292252 DOI: 10.1007/s12262-020-02173-3]

94 **Bailey C**, Black JRM, Swanton C. Cancer Research: The Lessons to Learn from COVID-19. *Cancer Discov* 2020; **10**: 1263-1266 [PMID: 32669285 DOI: 10.1158/2159-8290.CD-20-0823]

95 **Wei EK**, Long T, Katz MH. Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery. *JAMA Intern Med* 2021 [PMID: 34297056 DOI: 10.1001/jamainternmed.2021.4237]

96 **El-Sherif DM**, Abouzid M, Elzarif MT, Ahmed AA, Albakri A, Alshehri MM. Telehealth and Artificial Intelligence Insights into Healthcare during the COVID-19 Pandemic. *Healthcare (Basel)* 2022; **10** [PMID: 35206998 DOI: 10.3390/healthcare10020385]

97 **Yu C**, Helwig EJ. The role of AI technology in prediction, diagnosis and treatment of colorectal cancer. *Artif Intell Rev* 2022; **55**: 323-343 [PMID: 34248245 DOI: 10.1007/s10462-021-10034-y]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 1, 2022

**First decision:** May 28, 2022

**Article in press:** August 6, 2022

**Specialty type:** Surgery

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu Z, China; Park J, South Korea **S-Editor:** Wang DM **L-Editor:** Filipodia **P-Editor:** Wang DM



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**